EP Patent

EP1216712A1 — Cyclodextrin-drospirenone inclusion complexes

Assigned to Bayer Pharma AG · Expires 2002-06-26 · 24y expired

What this patent protects

A clathrate between cyclodextrin (CD) and drospirenone (DRSP) was prepared and used in pharmaceutical compositions. By the method in which the CD-DRSP clathrate was prepared, inclusion complexes between β- cyclodextrin and DRSP of at least 1:1, 2:1 and 1:2 were made available. As…

USPTO Abstract

A clathrate between cyclodextrin (CD) and drospirenone (DRSP) was prepared and used in pharmaceutical compositions. By the method in which the CD-DRSP clathrate was prepared, inclusion complexes between β- cyclodextrin and DRSP of at least 1:1, 2:1 and 1:2 were made available. As part of an inclusion complex, drospirenone has an increased water solubility, which is advantageous for its use as a medicament for the treatment of menopausal symptoms and for female contraception.

Drugs covered by this patent

Patent Metadata

Patent number
EP1216712A1
Jurisdiction
EP
Classification
—
Expires
2002-06-26
Drug substance claim
No
Drug product claim
No
Assignee
Bayer Pharma AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.